Omega-3 carboxylic acids monotherapy and combination with statins in the management of dyslipidemia

Vasc Health Risk Manag. 2016 Dec 12;12:481-490. doi: 10.2147/VHRM.S58149. eCollection 2016.

Abstract

The 2013 American College of Cardiology/American Heart Association guidelines on cholesterol management placed greater emphasis on statin therapy given the well-established benefits in primary and secondary prevention of cardiovascular disease. Residual risk may remain after statin initiation, in part because of triglyceride-rich lipoprotein cholesterol. Several large trials have failed to show benefit with non-statin cholesterol-lowering medications in the reduction of cardiovascular events. Yet, subgroup analyses showed a benefit in those with hypertriglyceridemia and lower high-density lipoprotein cholesterol level, a high-risk pattern of dyslipidemia. This review discusses the benefits of omega-3 carboxylic acids, a recently approved formulation of omega-3 fatty acid with enhanced bioavailability, in the treatment of dyslipidemia both as monotherapy and combination therapy with a statin.

Keywords: hypertriglyceridemia; non-HDL-C; omega-3 carboxylic acids; residual risk; statin.

Publication types

  • Review

MeSH terms

  • Biological Availability
  • Biomarkers / blood
  • Carboxylic Acids / pharmacokinetics
  • Carboxylic Acids / therapeutic use*
  • Cardiovascular Diseases / diagnosis
  • Cardiovascular Diseases / etiology
  • Cardiovascular Diseases / prevention & control*
  • Drug Compounding
  • Drug Therapy, Combination
  • Fatty Acids, Omega-3 / pharmacokinetics
  • Fatty Acids, Omega-3 / therapeutic use*
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Hypertriglyceridemia / blood
  • Hypertriglyceridemia / complications
  • Hypertriglyceridemia / diagnosis
  • Hypertriglyceridemia / drug therapy*
  • Lipids / blood*
  • Risk Factors
  • Treatment Outcome

Substances

  • Biomarkers
  • Carboxylic Acids
  • Fatty Acids, Omega-3
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Lipids